TuHURA Biosciences Enters Material Definitive Agreement
Ticker: HURA · Form: 8-K · Filed: Dec 5, 2025 · CIK: 1498382
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
TL;DR
TuHURA just signed a big deal creating a new financial obligation.
AI Summary
On December 2, 2025, TuHURA Biosciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as Kintara Therapeutics, Inc., filed an 8-K report detailing this obligation.
Why It Matters
This filing indicates TuHURA Biosciences has entered into a significant agreement that creates a financial obligation, which could impact its financial health and future operations.
Risk Assessment
Risk Level: medium — Entering into new financial obligations can introduce financial risk if the company's ability to meet these obligations is uncertain.
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former company name
- December 2, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
FAQ
What type of material definitive agreement did TuHURA Biosciences enter into?
The filing states that TuHURA Biosciences, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
What is the nature of the direct financial obligation created by this agreement?
The filing indicates the creation of a direct financial obligation, but the specific terms and amount of this obligation are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 2, 2025.
What was TuHURA Biosciences, Inc. formerly known as?
TuHURA Biosciences, Inc. was formerly known as Kintara Therapeutics, Inc.
Where is TuHURA Biosciences, Inc. incorporated?
TuHURA Biosciences, Inc. is incorporated in Nevada.
Filing Stats: 814 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-12-05 17:00:25
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
- $3.0 million — an aggregate principal amount of up to $3.0 million (the "Loans") during a 30-day availabil
- $1.5 million — st Loan to the Company in the amount of $1.5 million simultaneously with the execution of th
- $1.81 — ny common stock at an exercise price of $1.81 per share (the closing price of the Com
Filing Documents
- hura-20251202.htm (8-K) — 52KB
- hura-ex10_1.htm (EX-10.1) — 21KB
- 0001193125-25-309853.txt ( ) — 188KB
- hura-20251202.xsd (EX-101.SCH) — 30KB
- hura-20251202_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Amendment to Secured Promissory Note and Loan Agreement As disclosed in a Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the "Company") on October 31, 2025, the Company previously entered into a Secured Promissory Note and Loan Agreement, dated October 27, 2025 (the "Loan Agreement"), with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the "Lender"). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3.0 million (the "Loans") during a 30-day availability period beginning on the date of the Loan Agreement (the "Availability Period"). The Lender advanced the first Loan to the Company in the amount of $1.5 million simultaneously with the execution of the Loan Agreement (the "First Loan"). On December 2, 2025, the Company and Lender entered into an amendment to the Loan Agreement (the "Amendment") pursuant to which (i) the Lender agreed to extend the Availability Period to December 5, 2025 and (ii) the Company and Lender agreed that warrants issuable to the Lender under the Loan Agreement would consist of a warrant to purchase 150,000 shares of Company common stock for each $1.5 million of funds borrowed under the Loan Agreement (including under the First Loan), prorated for borrowings less than $1.5 million. Except for the foregoing, the Amendment included no further changes to the original Loan Agreement. Following the execution of the Amendment, on December 2, 2025, the Company borrowed an additional $1.5 million from the Lender under the Loan Agreement (the "Second Loan"), which resulted in aggregate Loans of $3.0 million made to the Company under the Loan Agreement. On the same date, the Company issued to the Lender an additional warrant to purchase an aggregate of 234,783 shares of Company common stock at an exercise price of $1.81 per share (the closing price of the Company's common stock on the N
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No 10.1 Amendment to Secured Promissory Note and Loan Agreement 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: December 5, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer